MedTrace Logo

Post-exercise Insulin Reductions in Type 1 Diabetes

NCT01531855 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2014-08-04

No results posted yet for this study

Summary

The investigators hypothesise that reducing rapid-acting insulin dose after exercise will help prevent Type 1 diabetes individuals experiencing hypoglycaemia.

Conditions

Interventions

OTHER

Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose

Dosage after exercise

Sponsors & Collaborators

  • Diabetes UK

    collaborator OTHER

  • Northumbria University

    lead OTHER

Principal Investigators

  • Daniel J West · Northumbria University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United Kingdom

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01531855 on ClinicalTrials.gov